Overview
SNY market data
Price History
SNY price chart
Valuation & Profitability
- P/E (TTM)
- 7.84 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.37 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.92 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 515.5% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $71.25 – $91.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $95.9K · P/B 1.41 · P/S 1.35.
Company News
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B EstimateBenzinga · Jul 30, 2026, 5:33 AM
Sanofi Drops Dupixent Successor Candidate After Assessing DataBenzinga · Jul 24, 2026, 6:10 PM
Communiqué de presse: Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondialesGlobenewswire Inc · Jul 24, 2026, 11:01 AM
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviewsGlobenewswire Inc · Jul 24, 2026, 11:01 AM
Scribe Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobenewswire Inc · Jul 24, 2026, 11:01 AM
Sanofi Discontinues Amlitelimab Development In Atopic Dermatitis, Will Not Submit For Global Regulatory Reviews After Strategic Pipeline AssessmentBenzinga · Jul 24, 2026, 6:42 AM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading WarningsBenzinga · Jul 16, 2026, 5:29 PM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM